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Agaricus  brasiliensis  is  an  edible  mushroom,  traditionally  used  for  the  treatment  of  several  diseases.  In
this paper,  a polysaccharide  (PLS)  from  A.  brasiliensis,  its  carboxymethylated  (CPLS)  and  sulfated  (SPLS)
derivatives,  as  well  as,  fractions  (F1–F3)  obtained  from  the  PLS  were  investigated  for  their  effect  in  the





inhibited  both  virus  strains  similarly,  in  a  dose-dependent  curve.  F1,  F2 and  CPLS  did not  show  signiﬁcant
effect  even  at higher  concentrations.  All  the  compounds  showed  neither  virucidal  or viral adsorption
inhibition  activities  nor  effect  when  cells  were  treated  prior  to  infection.  Our  study  demonstrated  that
the  extracts  of  A.  brasiliensis,  can  be promising  for future  antiviral  drug  design  and  its  biotechnological
production  is economically  feasible.ovine herpesvirus
. Introduction
Herpes simplex virus (HSV) and bovine herpes virus (BoHV) are
nveloped, double-stranded DNA virus, belonging to the Herpesviri-
ae family, Alphaherpesvirinae subfamily, responsible for mild to
evere diseases in human and bovine. HSV-1 also referred to as
uman herpes virus type 1 (HHV-1), a member of the Simplexvirus
enus, is one of the most regular human pathogens, being a public
ealth problem and the causal agent of several diseases estimated
o occur in approximately 40–80% of world population [1].  The
ariety of infections is manifested with different degrees of sever-
ty, from superﬁcial lesions to encephalitis, the latter, especially in
mmunocompromised patients. In Brazil, HSV-1 is one of the main
auses of viral encephalitis [2].
BoHV-1, classiﬁed under the Varicellovirus genus, shares many
iological properties with HSV-1 [1].  The virion is associated to sev-
ral syndromes in cattle and buffaloes, including infectious bovine
hinotracheitis (IBR), infectious pustular vulvovaginitis (IPV) and
nfectious pustular balanoposthitis (IPB). These diseases occur
hroughout the world and are responsible for signiﬁcant losses
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in the cattle industry. It has been estimated that BoHV-1 infects
50–90% of the Brazilian cattle population [3].
The infections caused by both agents are characterized by a short
replication cycle and the ability to induce latent infection, mainly in
sensory neurons [4]. These viruses establish a persistent infection
and can be life threatening and affect greatly the quality of the host
life. The latency reactivation cycle of herpesvirus has a deep epi-
demiological impact, since it is responsible for the maintenance of
HSV-1 and BoHV-1 in human and cattle population, respectively [4].
No proved effective vaccines are presently available for HSV infec-
tions and, although vaccines for BoHV-1 are available, none is able
to prevent the establishment of latency [5].  Acyclovir continues to
be the reference drug for HSV diseases treatment even after three
decades of its development [6].  However, in long-term treatment
and especially in immunocompromised individuals, acyclovir can
lead to the selection of resistant mutants [7].  These features high-
light the need to develop new antiherpetic drugs. Over the past
few years great efforts have been made to identify new and potent
antiviral drugs which are also active against latency establishing
virus [8].
Agaricus brasiliensis (syn Agaricus blazei,  Agaricus subrufescens),
commonly known as the Cogumelo do Sol®, ABM, Himematsutake,
and Cogumelo de Deus, is a native Brazilian basidiomycete [9].  It is
Open access under the Elsevier OA license.often consumed as food and tea worldwide, because of its medicinal
effects, such as, relief of physical and emotional stress, treatment
for high cholesterol, diabetes, gastric disorders and osteoporo-
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timulator [10]. Some studies report the antiviral activity of extracts
nd compounds from mycelium or fruiting body of A. brasiliensis at
eplication of poliovirus (PV), Western equine encephalitis (WEE),
epatitis B (HBV) and C (HCB) virus and HSV-1 and HSV-2 [11–16].
he aim of the present study was to investigate the antiviral activ-
ty of an A. brasiliensis polysaccharide, its fractions, as well as, its
arboxymethylated and sulfated derivatives in the replication of
SV-1 and BoHV-1.
. Materials and methods
.1. Cells and virus
HEp-2 cells (human laryngeal epithelial carcinoma cell, ATCC
CL-23) were grown at 37 ◦C in Dulbecco’s modiﬁed Eagle’s
edium (DMEM) (*Invitrogen – Gibco, USA), supplemented with
0% fetal bovine serum (*) and treated with 100 g/ml strepto-
ycin (*), 100 IU/ml penicillin (Novafarma Indústria Farmacêutica,
razil) and 2.5 g/ml amphotericin B (Meizler Biopharma S/A,
razil). Herpes simplex virus type 1 (HSV-1) and bovine herpesvirus
ype 1 (BoHV-1) provided, respectively, by DV/IMPG/UFRJ, Brazil
nd DMVP/UEL, Brazil, were propagated in HEp-2 cells, stocked at
20 ◦C with 10% glycerol.
.2. Compounds
The A. brasiliensis PLS, its fractions F1–F3, and its derivatives
ulfated (SPLS) and carboxymethylated (CPLS) were prepared, as
reviously described [17–19].
.3. Cytotoxicity assay
Cell viability was assayed by MTT  method (Sigma Chem. Co.,
SA), according to manufacturer’s instructions. Brieﬂy, 70% con-
uent cell cultures in 96-well microplates (Nunc A/S, Denmark)
ere treated with 500 g/ml, 1000 g/ml, 1500 g/ml, 2000 g/ml
nd 2500 g/ml of the compounds, in maintenance medium, with
ppropriate controls and maintained at 37 ◦C with 5% CO2, dur-
ng 72 h. The medium was replaced with 10 l of the MTT reagent
dimethylthiazolyldiphenyltetrazolium bromide) (1.25 g/ml) and
ncubated, under same conditions, for 3 h. The solubilizer agent was
dded and after 15 min  the absorbance read at 570 and 690 nm The
0% cytotoxic concentration (CC50) was calculated by the regres-
ion analysis of the obtained curves, and deﬁned as the compound
oncentration capable of reducing the OD of the MTT  product by
0% in relation to the control.
.4. Plaque reduction assay (PRA)
Antiviral activity was evaluated by plaque reduction assay,
s previously [20]. Brieﬂy, HEp-2 cell monolayers grown in 24-
ell plates (TPP, Switzerland) were infected with 50–100 PFU and
reated with 200 g/ml, 400 g/ml, 600 g/ml and 800 g/ml of
ach compounds. Infected and treated cells were washed and over-
aid with nutrient agarose (2×  DMEM/1.8% agarose) and 25 mM
f MgCl2 was added [21]. After 40 h cells were ﬁxed with 10%
ormaldehyde in PBS, pH 7.3, and stained with 0.5% crystal violet
n 20% ethanol. Plaques were counted and the percentage of viral
nhibition (%VI) was calculated as follows: %VI = [1 − (Vd/Vc)] × 100,
here Vd and Vc refer to the number of plaques in the presence
nd absence of the compounds, respectively [22]. The inhibitory
oncentration 50% (IC50), the amount of the compounds capable
o reduce in 50% the number of the plaques, was  calculated. The
electivity index (SI) was calculated as the ratio of CC50 and IC50.
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human interferon alfa-2B (Meizler Biopharma S/A, Brazil) were
used as positive control against HSV-1 and BoHV-1 replication.
For the time-of-addition assay, the concentrations of the com-
pounds, as before, were tested as previously described [23]. Brieﬂy
Protocol 1: cell cultures were placed in contact with the com-
pounds either for 1 h or 2 h, followed by compounds removal prior
to infection. Protocol 2: cell cultures treatment with the com-
pounds simultaneously to infection (0 h) and left throughout and
Protocol 3: cell cultures treatment with the compounds 1 h or 2 h
post-infection and left throughout. For the inhibitory effect of the
compounds on virus adsorption, cell cultures were maintained at
4 ◦C for 1 h followed by the infection in the presence of the com-
pounds at the same concentrations as before, for 80 min  at 4 ◦C. The
cell cultures were washed with cold PBS to remove nonadsorbed
virus followed by PRA [24]. For the virucidal assay, virus suspension
was incubated with varying concentrations of the compounds (v/v),
for 1 h at 37 ◦C in water bath. Treated virus suspension was diluted
to the tenth and the residual infectivity determined by plaque assay
[25].
2.5. Immunoﬂuorescence assay (IFA)
IFA was performed with HEp-2 cells grown in 24-well plates
with glass coverslips, infected with 100 l of HSV-1 or BoHV-
1 (moi approximately to 1) and treated with the compounds at
200 g/ml, 400 g/ml, 600 g/ml and 800 g/ml, at the time of
infection (0 h). Brieﬂy, 24 h post-infection, the cells were washed
with 0.05% Tween-20 PBS, ﬁxed with cold acetone (−20 ◦C) and
blocked with powdered skimmed milk PBS. The cells were incu-
bated either with mouse anti-HSV-1 (Santa Cruz Biotechnology,
USA) or bovine anti-BoHV-1 antibodies (DMVP/UFSM, Brazil) and
further washed with 0.05% Tween-20 PBS, then incubated with goat
anti-mouse IgG (Sigma Chem. Co., USA) and rabbit anti-bovine IgG
FITC conjugate (Sigma Chem. Co., USA), respectively. The cells were
examined in a Zeiss ﬂuorescence microscope (Imager A1 with Axio
Cam MRc5) and 100 cells/coverslip were counted and the percent-
age of ﬂuorescent cells calculated in comparison to control infected
and nontreated cells [33].
2.6. Statistics
Anova’s test followed by Turkey’s test (BioEstat 5.0 for Windows
XP, 2007) was used throughout. Values of p < 0.05 were considered
signiﬁcant.
3. Results
3.1. Compounds and characterization
A polysaccharide-complex and its fractions (F1–F3) were
extracted and characterized by 13C and 1H NMR [17], presenting
(1 → 6) and (1 → 4) glucan–protein polysaccharide constituted
mainly by -glucans. The (1 → 4) conﬁguration showing a signif-
icant reduction on the fractionation proceeded (F1–F3) [17].
3.1.1. 13C NMR spectroscopy from PLS, CPLS and SPLS
The 13C NMR  results of the isolated polysaccharides (Table 1)
were in good agreement with those presented previously [17]. The
structural characteristics of the polysaccharide and its fractions
(F1–F3) presented (1 → 6) and (1 → 4) glucan with the predomi-
nance of (1 → 6) reported in literature as having the most effective
pharmacological response relative to antitumoral and immunosup-
pressive activities. The (1 → 4) conﬁguration showing a signiﬁcant
reduction on the fractionation proceeded (F1–F3). The 13C NMR
spectrum of CPLS showed a peak of (C O) in 175 ppm, demonstrat-
ing the carboxymethylation (Table 1). The group sulfate generally
K.A. Yamamoto et al. / International Journal of Biological Macromolecules 52 (2013) 9– 13 11
Table  1
13C NMR  assignments for PLS, CPLS and SPLS systems from Agaricus brasiliensis.
System Chemical shift (ppm)
C1 C2 C3 C4 C5 C6 C O
PLS/ (1 → 6) 103 73,1 75.6 69.5 74.9 68.3 –
PLS/  (1 → 4) 99.8 71.5 75.3 78.7 71.2 60.1 175.0
CPLS/ (1 → 6) 103.5 75.5 82.9 73.9 76.7 70.7 –
































Antiviral activity of polysaccharide (PLS), sulfated derivative (SPLS) and fraction F3 of
Agaricus brasiliensis against herpes simplex virus-1 (HSV-1) and bovine herpesvirus-
1  (BoHV-1) by the plaque reduction assay, in HEp-2 cells. Cell cultures were treated
with the compounds (200–800 g/ml) at the time of the infection (time 0 h).
CC50 a HSV-1 BoHV-1
IC50 b SIc IC50 SI
PLS >2500 454 >5.5 634 >3.9
SPLS >2500 346 >7.2 830 >3.0
F3 >2500 0 – 674 >3.7
a
concentrations. The CPLS derivative was tested at higher concentra-
tions and demonstrated low activity (not shown). The compounds
F1 and F2 demonstrated highest %VI when added 1 h after infection,a  conﬁguration.
b  conﬁguration.
ccurs at the carbon 4 (C4) of conﬁguration (1 → 6) and at the
arbon 6 (C6) of conﬁguration (1 → 4). The introduction of sulfate
roups in the SPLS was conﬁrmed by displacement of C4 (glucan
n  conﬁguration), from 69.5 to 70.7 ppm and of C6 (glucan in 
onﬁguration) from 60.1 to 61.7 ppm (Table 1). The introduction of
he sulfate group generally occurs at the carbon 4 (C4) of conﬁgu-
ation (1 → 6) and preferably at the carbon 6 (C6) of conﬁguration
(1 → 4).
.1.2. FT-IR spectroscopy
The FT-IR spectra of PLS, CPLS and SPLS (Table 2) showed char-
cteristic bands of the presence of carbohydrates [26] relative
o OH (3000–3500 cm−1), CO (1034 cm−1) groups, to the C O C
1150 cm−1) and of proteins (1653, 1562 and 1242 cm−1) [27,28].
he band around 1739 cm−1 of the CPLS spectrum is characteris-
ic of stretch C O due to carboxymethylation. The sulfatation was
onﬁrmed by the presence of the band in 1262 cm−1 that refers to
he group (S O) observed in the SPLS spectrum [29,30].
.2. Cytotoxicity assay
The cytotoxic concentration of PLS, SPLS, CPLS and fractions
1–F3 for HEp-2 cells was above the highest concentration of the
ompounds used in this assay (2500 g/ml) (Table 3).
.3. Antiviral activity
.3.1. Anti-HSV-1
Out of the tested compounds, only PLS, SPLS and F3 presented
ntiviral activity against HSV-1 (Fig. 1). The time-of-addition assay
emonstrated that these extracts showed highest %VI when added
t the time of infection. The PLS presented the most effective result,
oreover, this activity was detected at the times 1 and 2 h after
he infection. The PLS %VI for the times 0 h, 1 h and 2 h were 77.5%,
3.6% and 2%, respectively, at the concentration of 800 g/ml. At the
able 2




3396 3436 3418  (O H) and (N H)
2930 2923 2927  (C H)
–  1739 –  (C O)
1653 1638 1647 as (COO−), amide I (C O)/protein
1562 1547 1547 (ı NH,  CN,  HCS) amide II/protein
1411 1420 1422 s (COO−)
–  – 1262  (S O) ester sulfate
1242 1250 1240 (ı NH,  CN) amide III/protein
1150 1149 1154  (C O C) glycosidic ether linkage
1079 –a 1081  (C1 H) anomeric carbon
1034 1039 1039  (C O) primary alcohol
858 –a 857 ı (C1 H) -glycosidic
– –  820 ı (C O S) group associated to the C O SO3
a Not clearly visible.Fifty percent cytotoxic concentration (CC50) for HEp-2 cells (g/ml).
b Fifty percent inhibitory concentration (IC50) (g/ml).
c Selectivity index (CC50/IC50).
same conditions, F3 showed %VI of 35.9%, 32.3% and 15%, respec-
tively, and the SPLS presented inhibition only at the time 0 h, about
82%. The PLS and F3 did not inhibit HSV-1 when added at 2 h and
1 h before infection and did not demonstrate any direct effect on
virus particle or inhibited virus adsorption either, at the indicatedFig. 1. The time-of-addition assay of polysaccharide (PLS) (a), the sulfated derivative
(SPLS) (b) and fraction F3 (c) of Agaricus brasiliensis in the replication of herpes
simplex virus (HSV-1) by plaque reduction assay, in HEp-2 cells. The substances were
added at varying concentrations (200–800 g/ml) before (−2 h and −1 h), during
(0  h) and after (1 h and 2 h) infection. The data are expressed as mean ± S.D (n = 3).
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Table  4
The effect of polysaccharide (PLS), sulfated derivative (SPLS) and fraction F3 of Agar-
icus brasiliensis against herpes simplex virus-1 (HSV-1) and bovine herpesvirus-1
(BoHV-1) replication by immunoﬂuorescence assay, in HEp-2 cells. The substances
were added at the time 0 h of infection.
HSV-1 BoHV-1
PLS SPLS F3 PLS SPLS F3
200a 14.8b 7.4 1.6 30.3 5.1 9.9
400  18.5 34.4 10.6 37.1 17.4 17
600  33.3 60.0 36.9 48.1 24.6 33.7











































Fig. 2. The time-of-addition assay of polysaccharide (PLS) (a), the sulfated derivative
(SPLS) (b) and fraction F3 (c) of Agaricus brasiliensis in the replication of bovinea g/ml.
b Percent of ﬂuorescent cells reduction in comparison to infected and nontreated
ells.
ith 20% of viral inhibition, and, at the same conditions, F3
nhibited 32.3% of HSV-1 replication. The IC50 for PLS was  454 g/ml
ith a SI > 5.5, while SPLS IC50 was 346 g/ml with SI > 7.2 (Table 3).
The PLS, SPLS and F3 effect in the synthesis of HSV-1 protein
emonstrated reduction of ﬂuorescent cells number up to 53.7%,
5.2% and 44.5%, respectively, at the highest tested concentration,
hen added at the time 0 h of the infection (Table 4).
.3.2. Anti-BoHV-1
The effect of PLS, SPLS and F3 for BoHV-1 was  similar to that
ound for HSV-1. Signiﬁcant inhibition was detected when PLS, SPLS
nd F3 were added at the time 0 h, 1 h and 2 h after the infection.
ig. 2 shows the results of time-of-addition assay of PLS, SPLS and F3
t the indicated concentrations. When the compounds were added
t the highest concentration at 0 h, and 1 h and 2 h post-infection,
he inhibition rates were 29.3%, 69.2% and 23.4%, respectively, for
LS. For SPLS, 53.6%, 28.6% and 41.5%, and for F3 28.0%, 77.4% and
7.3%. The CPLS, F1 and F2 showed no signiﬁcant inhibition (not
hown). None of the compounds showed direct effect on BoHV-1
r inhibited viral adsorption. For PLS the IC50 was  634 g/ml and
I > 3.9. For SPLS the IC50 was 830 g/ml and SI > 3, while, for F3 the
C50 was 674 g/ml and SI > 3.7 (Table 3).
The results of IFA showed that, when the compounds were
dded at the moment of infection (time 0 h), there were reductions
f ﬂuorescent cells up to 59.1%, 44.9% and 50.5%, for PLS, SPLS and
3 respectively, at the concentration of 800 g/ml (Table 4).
.4. Positive control
Acyclovir at 2500 g/ml inhibited the HSV-1 by 67%, while
oHV-1 was completely inhibited by interferon at 1000 U/ml.
. Discussion
The antiviral activity of compounds (PLS, SPLS, CPLS and frac-
ions) obtained from A. brasiliensis mycelium and fruiting body
as studied in the replication of human and bovine herpesvirus.
e demonstrated that the PLS, SPLS and F3 inhibited the replica-
ion of both virus with %VI varying from 30 to 80% at the highest
sed concentration (800 g/ml). The inhibition occurred when cells
ere treated with the compounds simultaneously to the infec-
ion and when treatment was performed after infection. However,
o effect was shown for virucidal, attachment inhibition or treat-
ent prior to infection protocols, at the concentrations used. These
esults are in agreement with similar experiments carried out with
xtracts of A. brasiliensis in herpesvirus and poliovirus infection, in
hat inhibitory effect was observed when cells were treated with
xtracts at the time of infection or when treatment was  followed
he infection [13,14,16].  Interestingly, we demonstrated that orig-
nal nonsulfated PLS showed better inhibition than the sulfated
erivative and F3 fraction due to the extended effect observed atherpesvirus (BoHV-1) by plaque reduction assay, in HEp-2 cells. The substances were
added at varying concentrations (200–800 g/ml) before (−2 h and −1 h), during
(0  h) and after (1 h and 2 h) infection. The data are expressed as mean ± S.D (n = 3).
the time 1 h after infection. The %VI was  83.6% to HSV-1 and 69.2%
to BoHV-1 at the concentration of 800 g/ml. It was  demonstrated
that aqueous extract of A. brasiliensis inhibited HSV-1 by 47.3% and
BoHV-1 by 20.9% at the concentration of 100 g/ml. Additionally, it
was also found that the inhibition of poliovirus, a single-stranded
RNA virus (PV-1) was  inhibited by 67% with similar PLS at the con-
centration of 200 g/ml [13,14]. However, it was  also shown that
A. brasiliensis mycelium original nonsulfated PLS did not inhibit
HSV-1 at the concentration of 20 g/ml, but, the sulfated deriva-
tive did [16]. These results demonstrated that the antiviral effect
of natural compounds from A. brasiliensis,  without chemical mod-
iﬁcation, requires concentrations of above 100 g/ml. Of the PLS
derivatives presently used, only the sulfated form demonstrated
stronger inhibition for both HSV-1 and BoHV-1 replication, when
the cells were treated simultaneously to infection. Similar ﬁnd-
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zadirachta indica [33], sulfated -glucans [34] and sulfated deriva-
ives. Overall, we suggest that antiherpetic activity of sulfated
olysaccharides could be through different mechanisms, includ-
ng virucidal and adsorption inhibition effects. In our study, only
PLS presented a small %VI (34%) for the inhibition adsorption pro-
ocol and 6% for virucidal assay even at the highest concentration
sed (800 g/ml). The insigniﬁcant inhibition of viral adsorption by
he original nonsulfated polysaccharide (PLS) conﬁrmed that the
resence of sulfate groups is required for such activities [31,35,36].
ther studies similarly reported no virucidal effects of sulfated
olysaccharides [37,38,32,39,40], however, when this effect was
escribed it was detected only at concentrations much higher than
heir IC50 [31,41,24].  Nevertheless, SPLS activity was improved only
hen used at the moment of the infection, therefore, this chemical
odiﬁcation, as well as, carboxymethylation, could not be neces-
ary.
The non-signiﬁcant virucidal, adsorption inhibition and pre-
reatment activities found in our study are in agreement with
revious studies [11,12,14–16]. In contrast, it was  found that
queous extract of A. brasiliensis presented virucidal activity to
erpesvirus [13], however, this effect could be synergistically pro-
oted by substances present in crude preparation, but, absent in
uriﬁed PLS.
The present results suggest that the compounds (PLS, F3 and
PLS) act at early steps of the HSV-1 and BoHV-1 replication. The
nhibition of viral protein synthesis could be one of the steps, as
emonstrated by dose-dependent inhibition of HSV-1 by SPLS fol-
owed by other compounds for both viruses when treatment was
imultaneously to infection by IFA.
The A. brasiliensis PLS is a glucan–protein complex, presenting
 and  glycosidic linkage. -Glucans being predominant to which
he antiviral activity may  be attributed. Some PLS rich in -glucans,
ike PSK from kawaratake, lentinan from shiitake and shizophyllan
rom suehirotake are effective against several viral agents [42]. The
-glucans can decrease viral nucleic acid levels in cells infected
nd stimulate the immune system by binding to Toll-like receptors
nd dectins and causes the induction of various cytokines, among
hem the interferon [43]. The polysaccharides can induce interferon
nd, consequently, antiviral state by stimulation of intracellular
ignaling pathways [44]. This mechanism has already been pro-
osed for A. brasiliensis for patients infected with hepatitis B [15]
nd for hepatitis C virus [12], in which it was detected the induc-
ion of the interferon receptor suggesting that the extracts could be
seful for patients who do not respond to interferon treatment.
In addition, of the fractions (F1–F3) analyzed, only F3 showed
mall inhibition both HSV-1 and BoHV-1 replication. When the PLS
s fractioned, the -glucans content increased [17], therewith F3
as a higher % of -glucans that may  be related to their greater
ctivity compared to F1 and F2.
In summary, our ﬁndings indicated that of the tested com-
ounds, PLS and SPLS were the most efﬁcient to inhibit herpesvirus
eplication, interfering at the initial steps, such as, penetration,
ncoating and protein synthesis inhibition. Our results alongside
o those previously obtained suggest that A. brasiliensis extracts can
e promising for the future antiviral drug design.
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